Daiichi Sankyo Company, Limited

Mie University

Mitsubishi Electric Corporation

Kento Tanaka

Kensuke Nakamura

Ryuji Hashimoto

Hiroshi Shiku

Takako Kimura

Toshiaki Ohtsuka

Ichiro Watanabe

Makiko Nakayama

Naoya Shinozaki

Takashi Kagari

Junya Ichikawa

Shiho Kozuma

Tomoaki Komai

Yasushi Akahori

Daichi Baba

Ayaka Yatsu

Yoshikuni Onodera

Shinji Furuzono

Anri Aki

Nobumi Nagaoka

An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Bispecific antibody

An adjustment device is configured to collect estimation results of the estimated state of the occupant; determine whether or not it is necessary to check the state of the occupant on the basis of the estimation results; determine a behavior of the occupant on the basis of behavior determination information and set the state of the occupant when it is determined that it is necessary to check the state of the occupant; and output adjustment information for causing an occupant state estimating device to adjust a state estimation condition used for estimating the state of the occupant so that the estimation result of the state of the occupant becomes the set state of the occupant.

Adjustment device, adjustment system, and adjustment method

A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.

Anti-Orai1 antibody

Growing community of inventors

Kanagawa, Japan

Kento Tanaka